Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Monoclonal Antibody

Anti-Human free PSA/fPSA Monoclonal Antibody (1A277)

Catalog #:   MHC24208 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG
Applications: ELISA
Overview

Catalog No.

MHC24208

Species reactivity

Human

Host species

Mouse

Isotype

IgG

Clonality

Monoclonal

Immunogen

Human free PSA/fPSA Protein.

Target

Prostate-specific antigen, PSA, 3.4.21.77, Gamma-seminoprotein, Seminin, Kallikrein-3, P-30 antigen, Semenogelase, KLK3, APS

Concentration

1mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

1A277

Data Image
References

Design, characterization, and validation of a high-affinity synthetic peptide as bioreceptor for label-free detection of prostate specific antigen., PMID:40505236

PSMA targeted Therapy: From molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer., PMID:40466338

High-Efficiency Detection of Total-PSA and Free-PSA in Whole Blood by Microfluidic Chip Integrated with Electromagnetic Co-Preprocessing., PMID:40456626

Polarity-Switchable Dual-Mode Photoelectrochemical Cancer Marker Immunoassay Based on a Metal-Organic Framework@Nitrogen-Doped Graphdiyne Heterojunction., PMID:40304230

A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma., PMID:40145367

Gold Nanoparticle Incorporated Graphene Oxide as a SERS Platform for Ultratrace Antibody Free Sensing of the Cancer Biomarker CEA., PMID:40062598

Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer., PMID:39964352

Label-free electrochemical immunoassay for ultra-sensitive detection of PSA utilizing gold nanoparticles/polyhedral hollow CoCu bimetallic sulfide nanostructure as a dual signal amplification platform., PMID:39884638

Effective Use of Euphorbia milii DCM Root Extract Encapsulated by Thermosensitive Immunoliposomes for Targeted Drug Delivery in Prostate Cancer Cells., PMID:39590308

Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer., PMID:39503807

Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion-positive non-small cell lung cancer in the United States., PMID:39352419

Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects., PMID:39330991

Platinum-perovskite nanocomposite-based Exosensor for specific detection of prostate cancer in clinical settings., PMID:39261334

Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D., PMID:38926066

Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States., PMID:38855109

A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer., PMID:38838502

Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis., PMID:38811891

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial., PMID:38787530

Lectin-nanoparticle concept for free PSA glycovariant providing superior cancer specificity., PMID:38677453

Membrane-Free Lateral Flow Assay with the Active Control of Fluid Transport for Ultrasensitive Cardiac Biomarker Detection., PMID:38659215

Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study., PMID:38498504

A NiFe PBA/AuNPs nanocomposite sensitive immunosensor for electrochemical detection of PSA., PMID:38497295

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer., PMID:38430405

Phage Display's Prospects for Early Diagnosis of Prostate Cancer., PMID:38400052

Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer., PMID:38383374

Smartphone-Based Free-to-Total Prostate Specific Antigen Ratio Detection System Using a Colorimetric Reaction Integrated with Proximity-Induced Bio-Barcode and CRISPR/Cas12a Assay., PMID:38342699

Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials., PMID:38331400

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer., PMID:38300720

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial., PMID:38167882

Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer., PMID:38101860

Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study., PMID:37940446

Evaluation of enhanced permeability effect and different linear energy transfer of radionuclides in a prostate cancer xenograft model., PMID:37736493

Investigating on sensing mechanism of MoS2-FET biosensors in response to proteins., PMID:37506679

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer., PMID:37386633

Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China., PMID:37313403

Electrochemical immunoassay for one-pot detection of thyroxin (T4) and thyroid-stimulating hormone (TSH) using magnetic and Janus nanoparticles., PMID:37254003

SERS-based biosensor for detection of f-PSA%: Implications for the diagnosis of prostate cancer., PMID:37196403

Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer., PMID:36918939

Shrink polymer based electrochemical sensor for point-of-care detection of prostate-specific antigen., PMID:36906988

Rational design of nonlinear hybridization immunosensor chain reactions for simultaneous ultrasensitive detection of two tumor marker proteins., PMID:36857646

A sensitive label-free biosensor based on Ag2S-sensitived Bi2WO6/BiOBr heterojunction for photoelectrochemical immunoassay of prostate specific antigen., PMID:36791596

Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol., PMID:36717150

METCAM Is a Potential Biomarker for Predicting the Malignant Propensity of and as a Therapeutic Target for Prostate Cancer., PMID:36672713

Targeted Mass Spectrometry Assays for Specific Quantification of Urinary proPSA Isoforms., PMID:36626706

Gold Nanoparticles-MWCNT Based Aptasensor for Early Diagnosis of Prostate Cancer., PMID:36551097

Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients with Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations., PMID:36455946

Kinetic Analysis of Prostate-Specific Antigen Interaction with Monoclonal Antibodies for Development of a Magnetic Immunoassay Based on Nontransparent Fiber Structures., PMID:36432177

Glucose oxidase-encapsulated liposomes for amplified autofluorescence-free immunoassay of a prostate-specific antigen with photoluminescence of CePO4:Tb nanocrystals., PMID:36416489

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial., PMID:36394849

Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study., PMID:36289372

Datasheet
$ 196
Product specifications
50 μg 196 100 μg 313

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human free PSA/fPSA Monoclonal Antibody (1A277) [MHC24208]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only